| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/12/2004 | US20040029801 Antiinflammatory agents; immunosuppressants; inflammatory bowel disease; antiarthritic agents; autoimmune diseases; administering drug and immunosuppressant |
| 02/12/2004 | US20040029793 Genetic engineering; antibodies; antiinflammatory agents, circulation diseases, anticancer agents, antidiabetic agents, gastrointestinal disorders |
| 02/12/2004 | US20040029782 Antiinflammatory agents; osteoporosis; cardiovascular disorders; coating for prosthetics |
| 02/12/2004 | US20040029775 Methods and compounds for influencing beta3-integrin-dependent intracellular processes |
| 02/12/2004 | US20040029247 Regulation of human adenylate cyclase, type iv |
| 02/12/2004 | US20040029224 Used for determination of ligands (agonists), preparation of antibodies and antisera, construction of recombinant receptor protein expression systems, development of receptor binding assay systems and screening of pharmaceutical candidates |
| 02/12/2004 | US20040029222 Proteins and nucleic acids encoding same |
| 02/12/2004 | US20040029202 By determining a level of an estrogen- related marker; screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT; treating peri-, menopausal or postmenopausal women |
| 02/12/2004 | US20040029180 Method for identifying agonists or antagonists of the G protein-coupled receptor mas-like 1 |
| 02/12/2004 | US20040029178 For anti-obesity/appetite enhancing drugs; prolactin inhibitors |
| 02/12/2004 | US20040029163 Novel tissue-specific secretory polypeptide and dna thereof |
| 02/12/2004 | US20040029150 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/12/2004 | US20040029132 Nucleic acid and amino acid sequences of drug metabolizing enzymes; used in diagnosis, treatment, and prevention of autoimmune/ inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders |
| 02/12/2004 | US20040029117 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| 02/12/2004 | US20040028758 Antioxidant composition and method of preparation thereof |
| 02/12/2004 | US20040028753 Inhalation of nitric oxide |
| 02/12/2004 | US20040028752 Hemorrhoids therapy |
| 02/12/2004 | US20040028751 Compositions for preventing or ameliorating multiple risk factor syndromes |
| 02/12/2004 | US20040028743 Brandycardial agents |
| 02/12/2004 | US20040028728 Liposome preparations |
| 02/12/2004 | US20040028722 Microbial cellulose wound dressing for treating chronic wounds |
| 02/12/2004 | US20040028685 EphA2 monoclonal antibodies and methods of use thereof |
| 02/12/2004 | US20040028684 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/12/2004 | US20040028658 Methods of organ regeneration |
| 02/12/2004 | US20040028649 Regenerating cells |
| 02/12/2004 | US20040028644 Synergistic mixture |
| 02/12/2004 | US20040028619 Antiinflammatory agents; bronchodilator agents; antihistamines; respiratory system disorders |
| 02/12/2004 | DE10234192A1 Verwendung von Erythropoetin Use of erythropoietin |
| 02/12/2004 | DE10233366A1 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel In the 6-position substituted indolinone derivatives, their preparation and their use as medicaments |
| 02/12/2004 | DE10233229A1 Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels A pharmaceutical composition for lowering triglyceride levels |
| 02/12/2004 | CA2710100A1 Use of erythropoietin |
| 02/12/2004 | CA2494632A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 02/12/2004 | CA2494616A1 Furanthiazole derivatives as heparanase inhibitors |
| 02/12/2004 | CA2494607A1 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
| 02/12/2004 | CA2494421A1 Condensed pyridines and pyrimidines with tie2 (tek) activity |
| 02/12/2004 | CA2494408A1 Method and compounds for promoting healing and reducing inflammation |
| 02/12/2004 | CA2494308A1 Methods of use of compounds with preptin function |
| 02/12/2004 | CA2494146A1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 02/12/2004 | CA2494114A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 02/12/2004 | CA2493752A1 Papsss as modifiers of the axin pathway and methods of use |
| 02/12/2004 | CA2493637A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/12/2004 | CA2493598A1 Use of erythropoietin_to treat renal failure |
| 02/12/2004 | CA2493551A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 02/12/2004 | CA2397684A1 Mitochondrially targeted antioxidants |
| 02/11/2004 | EP1388535A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 02/11/2004 | EP1388534A2 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| 02/11/2004 | EP1388344A1 Composition comprising Salvia Miltiorrhizae, Ginseng, Borneol for treating heart disease, and cerebrovascular diseases |
| 02/11/2004 | EP1388343A1 Antioxidant composition and method of preparation thereof |
| 02/11/2004 | EP1388342A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/11/2004 | EP1388341A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/11/2004 | EP1388340A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient |
| 02/11/2004 | EP1388295A1 Cereal based food product comprising DHA |
| 02/11/2004 | EP1387895A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 02/11/2004 | EP1387889A2 Kinases and phosphatases |
| 02/11/2004 | EP1387888A2 Nucleic acid-associated proteins |
| 02/11/2004 | EP1387886A2 Proteases |
| 02/11/2004 | EP1387840A1 3,5-diamino-1,2,4-triazoles as kinase inhibitors |
| 02/11/2004 | EP1387838A1 Cyanoanthranilamide derivatives and the use thereof as medicaments |
| 02/11/2004 | EP1387833A1 Protease-inhibitors |
| 02/11/2004 | EP1387829A1 Novel pyridinone and related heterocyclic derivatives |
| 02/11/2004 | EP1387826A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors |
| 02/11/2004 | EP1387825A1 Thyroid hormone receptor antagonists for cardiac & metabolic disorders ii |
| 02/11/2004 | EP1387821A2 Estrogen receptor modulators |
| 02/11/2004 | EP1387688A2 Benzazepinone alpha v integrin receptor antagonists |
| 02/11/2004 | EP1387686A1 Timing and duration of administration of adenosine a1/a2 agonist for cardioprotection |
| 02/11/2004 | EP1387680A1 Benzimidazole derivatives as therapeutic agents |
| 02/11/2004 | EP1387679A1 Sulfonamides |
| 02/11/2004 | EP1328282A4 Efficient method for producing compositions enriched in anthocyanins |
| 02/11/2004 | EP1274702B1 Process for the synthesis of a known tetrazol derivative |
| 02/11/2004 | EP1144393B1 Benzoxazole derivatives for use as integrin inhibitors |
| 02/11/2004 | EP1086113B1 Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
| 02/11/2004 | EP1047411B1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation |
| 02/11/2004 | EP0888452B1 Human cyr61, an extracellular matrix signalling molecule |
| 02/11/2004 | CN1474818A Preventive or therapeutic medicines for diabetes, containing fused heterocycle compounds or their salts |
| 02/11/2004 | CN1474816A 4-amino-quinazolines |
| 02/11/2004 | CN1474815A 4-amino-quinazolines |
| 02/11/2004 | CN1474813A Substituted 2-phenylaminomidazoline phenyl ketone derivatives as IP antagonists |
| 02/11/2004 | CN1474810A Substituted urea neuropeptide YY5 antagonists |
| 02/11/2004 | CN1474805A 2-amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 02/11/2004 | CN1474702A Oral pharmaceutical composition containing a block copolymer |
| 02/11/2004 | CN1474693A Use of thienopyrimidines |
| 02/11/2004 | CN1474690A Synergestic combinations comprising renin inhibitor for cardiovascular diseases |
| 02/11/2004 | CN1474688A Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists |
| 02/11/2004 | CN1474687A Mdeicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 02/11/2004 | CN1474656A Improved bioactive whey protein hydrolysate |
| 02/11/2004 | CN1473838A Extracting and refining process for alfalfa saponin and alfalfa saponin preparation |
| 02/11/2004 | CN1473617A Pricklyash seed oil serial prearation and its preparing process |
| 02/11/2004 | CN1473614A Chinese medicine for treading apoplexy, cancer and other diseases |
| 02/11/2004 | CN1473599A Medicine for treating atherosclerosis and its preparing method |
| 02/11/2004 | CN1473595A Chinese medicine preparation for treating heart disease |
| 02/11/2004 | CN1473591A Medicine for curing pile and its preparing method |
| 02/11/2004 | CN1473584A Medicine for treating piles |
| 02/11/2004 | CN1473567A Combined therapeutic method including acrivastine and antihypertensive |
| 02/11/2004 | CN1473566A Combined therapeutic method including acrivastine and antihypertensive |
| 02/11/2004 | CN1137888C Inhibitor of cysteninyl aspartic acid proteinase |
| 02/11/2004 | CN1137884C Indazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use |
| 02/11/2004 | CN1137713C Chinese medicine oral preparation for curing apoplectic disease and its preparation method |
| 02/11/2004 | CN1137706C Medicine for treating hyperlipemia |
| 02/11/2004 | CN1137695C Plaster for curing hemiplegia and hypertension |
| 02/10/2004 | US6689909 Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |